AVROBIO - Model AVR-RD-02 - Gene Therapy for Gaucher Disease - Type 1
AVROBIO’s investigational gene therapy for Gaucher disease is being studied in a Phase 1/2 clinical trial to evaluate the safety and efficacy in individuals with Gaucher disease type 1. The trial is now enrolling in Canada, Australia and the U.S. The trial is intended to recruit 8 to 16 individuals between the ages of 16 and 35 with Gaucher disease type 1, including both those who are treatment-naïve and those who are stable on enzyme replacement therapy.
-
Most popular related searches
Customer reviews
No reviews were found for AVROBIO - Model AVR-RD-02 - Gene Therapy for Gaucher Disease - Type 1. Be the first to review!